Literature DB >> 16278777

Are routine testosterone assays good enough?

Sydney S Sacks1.   

Abstract

Entities:  

Year:  2005        PMID： 16278777      PMCID： PMC1240029     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN： 0159-8090


× No keyword cloud information.
  5 in total

Review 1.  Serum testosterone assays--accuracy matters.

Authors:  Alvin M Matsumoto; William J Bremner
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

2.  Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry.

Authors:  Christina Wang; Don H Catlin; Laurence M Demers; Borislav Starcevic; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

3.  Immunoassays for testosterone in women: better than a guess?

Authors:  David A Herold; Robert L Fitzgerald
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

4.  Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children.

Authors:  Joëlle Taieb; Bruno Mathian; Françoise Millot; Marie-Claude Patricot; Elisabeth Mathieu; Nicole Queyrel; Isabelle Lacroix; Claude Somma-Delpero; Philippe Boudou
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

5.  Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods.

Authors:  Karen K Miller; William Rosner; Hang Lee; Joan Hier; Gemma Sesmilo; David Schoenfeld; Gregory Neubauer; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958
  5 in total
  5 in total

1.  Accuracy-based proficiency testing for testosterone measurements with immunoassays and liquid chromatography-mass spectrometry.

Authors:  Zhimin Tim Cao; Julianne Cook Botelho; Robert Rej; Hubert Vesper
Journal:  Clin Chim Acta       Date:  2017-03-10       Impact factor: 3.786

2.  Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.

Authors:  Eija A Lundström; Rupert K Rencken; Johann H van Wyk; Lance J E Coetzee; Johann C M Bahlmann; Simon Reif; Erdam A Strasheim; Martin C Bigalke; Alan R Pontin; Louis Goedhals; Douw G Steyn; Chris F Heyns; Luigi A Aldera; Thomas M Mackenzie; Daniela Purcea; Pierre Y Grosgurin; Hervé C Porchet
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

3.  Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes.

Authors:  Kristine M Wiren; Xiao-Wei Zhang; Dawn A Olson; Russell T Turner; Urszula T Iwaniec
Journal:  Bone       Date:  2012-08-14       Impact factor: 4.398

Review 4.  Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes.

Authors:  Hussein Yassine; Chad R Borges; Matthew R Schaab; Dean Billheimer; Craig Stump; Peter Reaven; Serrine S Lau; Randall Nelson
Journal:  Proteomics Clin Appl       Date:  2013-07-09       Impact factor: 3.494

Review 5.  Challenges and improvements in testosterone and estradiol testing.

Authors:  Hubert W Vesper; Julianne C Botelho; Yuesong Wang
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.